Rankia España
Acceder

vilemos8

Rankiano desde hace más de 8 años
64
Publicaciones
51
Recomendaciones
--
Seguidores
Posición en Rankia
Posición último año
Resumen
Respuestas 64
Recomendados 2
Guardados 45
13/11/15 21:24
Ha respondido al tema Farmas USA
Creo haber leído que son acciones ordinarias que no salen al mercado, solo se emiten para la adquisición de DEPO mediante intercambio 0,95 a 1. Eso es lo que yo entiendo. HZNP
Ir a respuesta
13/11/15 20:16
Ha respondido al tema Farmas USA
HZNP Aprobada la emisión de 81.700.000 acciones ordinarias para la adquisición de DEPO Horizon Pharma plc Provides Update on Shareholders Meeting Related to the Proposed Acquisition of Depomed, Inc. Shareholders Approve the Issuance of up to 81,706,881 Ordinary Shares of Horizon Pharma plc in Connection With an Acquisition of Depomed, Inc.; Extends Exchange Offer to Acquire Depomed DUBLIN, IRELAND -- (Marketwired) -- 11/13/15 -- Horizon Pharma plc (NASDAQ: HZNP) ("Horizon Pharma"), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced that its shareholders have approved four of the five proposals put before them today at the extraordinary general meeting of Horizon Pharma shareholders (the "Shareholder Meeting"). Further details on the voting results for each of the proposals put before the shareholders at the Shareholder Meeting can be found on the Current Report on Form 8-K that Horizon Pharma intends to file with the Securities and Exchange Commission later today. "Today's overall favorable vote by our shareholders demonstrates the confidence they have in our team's ability to build value through the potential acquisition of Depomed," said Timothy P. Walbert, chairman, president and chief executive officer of Horizon Pharma plc. "We and other like-minded shareholders believe that a combination with Depomed is financially, operationally and strategically compelling and look forward to continued engagement with Depomed shareholders as we work towards achieving this important merger." By obtaining the approval of its shareholders on key proposals, Horizon Pharma has satisfied another of the conditions to its outstanding exchange offer to acquire all of the outstanding shares of common stock of Depomed. However, the exchange offer remains conditioned on, among other things, the redemption or removal of certain poison pill rights that the Depomed board has the unilateral ability to remove and the tender of a majority of the total number of outstanding Depomed shares on a fully diluted basis. Proposal four, which concerned powers under Irish law to issue beyond the previously-authorized 300 million shares for cash without first offering those shares to existing shareholders under pre-emptive rights and required 75 percent approval, received slightly less than the required "for" votes, but does not have any effect upon Horizon Pharma's current offer for Depomed. In order to provide sufficient time to satisfy the remaining conditions to its exchange offer, Horizon Pharma today also announced that it has extended the expiration of its exchange offer to acquire all of the outstanding shares of common stock of Depomed to 5 p.m., Eastern Time, on November 30, 2015. The exchange offer was previously scheduled to expire 5 p.m., Eastern Time on November 20, 2015. The depository of the exchange offer has advised that, as of 9:00 a.m., Eastern Time on November 13, 2015, a total of approximately 10,404 shares of Depomed common stock were validly tendered and not properly withdrawn in the exchange offer. Ahora falta que los accionistas de DEPO den su aprobación. HZNP
Ir a respuesta
11/11/15 14:46
Ha respondido al tema Farmas USA
HZNP Horizon Pharma plc Provides Comment on Express Scripts' Business Practices DUBLIN, IRELAND -- (Marketwired) -- 11/11/15 -- Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today commented on Express Scripts' business practices. "Our philosophy of ensuring that patients get the medicine their doctors prescribe is threatening Express Scripts' profiteering and exposing what we believe is a lack of care for patients and respect for physicians," said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma plc. "Express Scripts is not only a pharmacy benefit manager that has significant control over prescriptions that flow to specialty pharmacies, it also operates its own mail-order pharmacy and thus is a direct competitor of small, independent specialty pharmacies throughout the United States. This competitive role, in our view, creates a clear conflict of interest, as Express Scripts stands as both a pharmacy's overseer and competitor. In fact, Express Scripts' specialty pharmacy, Accredo Health Group, Inc., is the largest in the United States with more than 28 percent market share. Based on its Accredo ownership, it's not surprising that Express Scripts would target small, competitive independent specialty pharmacies in order to force those pharmacies from its network, attempt to dominate the U.S. specialty pharmacy medicine distribution channel and further boost its own profits at the expense of patients. As the New York Times reported on July 15, 2015, independent specialty pharmacies believe that insurers and pharmacy benefit managers funnel business to their own pharmacies, even if others may provide better service." "Additionally, we currently have an agreement with Accredo to provide one of our important orphan medicines to patients, and contrary to the misperception that Express Scripts wishes to create, Accredo accounts for a larger percentage of our revenue than any other pharmacy. However, based on current and past business practices by Accredo and Express Scripts, including its recent $60 million fraud settlement with the U.S. Department of Justice, we are re-evaluating this relationship to determine how we can most appropriately and ethically serve our patients, their physicians and our shareholders," Walbert continued. "Profiteering, particularly in the case of Express Scripts which recognized more than $38 billion in revenues from specialty and home-delivery services in 2014, and anti-competitive behavior has to stop because ultimately it's the patients who suffer and the impact on the patient is far reaching," Walbert added. "As Linden Care stated in its legal complaint, 'if Linden does not receive a stay pending a hearing, the termination will remain in effect, resulting in innocent patients potentially missing medications due to a physical inability to obtain them through other channels, experiencing withdrawal symptoms from narcotics or experiencing errors in taking medications, thereby placing their well-being in jeopardy.' This isn't the right thing to do for patients and as an industry that exists to serve the patient, we need to take a stand to ensure that regardless of the hurdles we face from pharmacy benefit managers, we continue to do whatever possible to ensure patients have access to the medicines their physicians prescribe." Statement Previously Released on November 10, 2015 Our primary concern is for the patients who, based on the profit driven actions of Express Scripts, may be denied access to medicines that are prescribed by their physicians. We are committed to ensuring that regardless of these actions, patients will have access to the medicines they need. Less than five percent of our net sales are from prescriptions that are filled by Linden Care and processed by Express Scripts. In addition, we have a diverse group of pharmacies that participate in our patient support program and no pharmacy that participates in our primary care patient support programs account for more than 13 percent of our net sales. The notion that Linden Care is a so-called "captive pharmacy" of Horizon Pharma is entirely false. At best Express Scripts is being reckless in its allegations and at worse it is intentionally attempting to mislead investors. As previously stated, all pharmacies that distribute Horizon branded medicines are fully independent. Horizon does not own or have an ownership stake in any pharmacy and does not possess an option to purchase any pharmacy. In addition, the relationship with these pharmacies is non-exclusive where each of these pharmacies may also fulfill prescriptions for other drug manufacturers. The lawsuit filed by Express Scripts relates entirely to a previously disclosed dispute concerning a prior rebate agreement between the parties. As we previously disclosed approximately one year ago, we terminated the contract with Express Scripts after Express Scripts failed to live up to its contractual obligations. Indeed, after we notified Express Scripts of its breaches, Express Scripts made no effort to cure the breaches, let alone respond to our notice, within the contractual deadline to terminate the contract. The substantial majority of the monetary damages Express Scripts is seeking to recover are for prescriptions that occurred after the termination of the contract. We are still reviewing the allegations in the complaint but we believe the claims are without merit and we intend to vigorously defend ourselves. In light of Express Scripts' actions, we will evaluate all legal and other remedies and options. Este comunicado es de la 13,35 de hoy, y por lo que leo la guerra es entre Express Scripts y Horizon, veremos cómo termina
Ir a respuesta
10/11/15 01:04
Ha respondido al tema Farmas USA
Horizon Pharma plc has filed the following document(s) with the United States Securities and Exchange Commission http://ir.horizon-pharma.com/secfiling.cfm?filingid=1193125-15-372193&CIK=1005201 Con solo ver las primeras páginas..... Impresiona. HZNP
Ir a respuesta
10/11/15 00:50
Ha respondido al tema Farmas USA
Arena Pharmaceuticals, Inc. has filed the following document(s) with the United States Securities and Exchange Commission. http://invest.arenapharm.com/secfiling.cfm?filingid=1628280-15-8555&CIK=1080709 ARNA
Ir a respuesta
09/11/15 23:43
Ha respondido al tema Farmas USA
Puede que se decida por cerrar el que dejó el 6/11 en 17,4 - 18,7 o que se vaya directamente a cerrar el que dejó el 22/09 en 28,7 - 27,7. Qui lo sa?. Personalmente prefiero que no deje nada pendiente. HZNP
Ir a respuesta
09/11/15 23:02
Ha respondido al tema Farmas USA
Gracias Triskis. Eso es lo que quería, opiniones. Estoy muy tranquilo, puesto que llevo en el valor desde Enero de 2013 y mi precio objetivo aún está muy lejos. Con respecto a la opa, será lo que quieran los accionistas de DEPO, pero si yo me encontrara entre ellos no dudaría en aceptar la oferta. HZNP
Ir a respuesta
09/11/15 21:17
Ha respondido al tema Farmas USA
Gracias Framus. Agradezco tus respuestas, pero no pedía información (esta me llega directamente de las web a las que estoy subscrito) pedía vuestra "opinión". Veo que estáis en otra cosa, pero igualmente agradezco la respuesta. Saludos HZNP
Ir a respuesta
09/11/15 19:14
Ha respondido al tema Farmas USA
Vale!!! Tampoco era necesario que opinárais todos a la vez sobre este tema, me hubiera conformado con un par de opiniones. Peeeeroooo....., comprendo que el tema del día es la cotización de NVAX. Lo siento, otra vez será. Gracias de todas formas. Os sigo leyendo. HZNP
Ir a respuesta
09/11/15 17:52
Ha respondido al tema Farmas USA
Horizon Pharma plc Announces 2016 Net Sales and Adjusted EBITDA Guidance; Reviews 2020 Long-Range Plan DUBLIN, IRELAND -- (Marketwired) -- 11/09/15 -- Full-Year 2016 Net Sales Guidance of $950 to $975 million Full-Year 2016 Adjusted EBITDA Guidance of $460 to $475 million 2020 Long-Range Plan Net Sales Estimated to Exceed $2 billion Long-Range Plan Estimates Orphan Business to Represent Approximately 60 percent of Net Sales in 2020 Viendo la cotización actual me cuadra perfectamente 1 share DEPO = 0,95 share HZNP. Creo que el actual Consejo de DEPO tiene los días contados. Se agradecen opiniones, puesto que voy casi all in en esta. HZNP
Ir a respuesta
23/10/15 19:39
Ha respondido al tema Farmas USA
Alguien puede comprobar si HZNP tiene hoy vencimiento de opciones? Si no es así, creo que algunos piratas estuvieron maniobrando para quedarse mis títulos. Menudo circo!!!
Ir a respuesta
06/10/15 01:13
Ha respondido al tema Farmas USA
On October 5, 2015, at the request of our Board of Directors, Jack Lief, our President, Chief Executive Officer and principal financial officer, retired from the company, including our Board, effective today. Más bien parece que "lo retiran" a petición del Consejo de Administración http://invest.arenapharm.com/secfiling.cfm?filingid=1628280-15-7552&CIK=1080709 ARNA
Ir a respuesta
05/10/15 13:28
Ha respondido al tema Farmas USA
Horizon Pharma plc Announces Expansion and Relocation of U.S. Corporate Headquarters http://ir.horizon-pharma.com/releasedetail.cfm?ReleaseID=935047 Reubicación y ampliación de su sede en USA, con capacidad para cerca de 600 trabajadores HZNP
Ir a respuesta
28/09/15 16:33
Ha respondido al tema Farmas USA
Cierto, y además cerró el gap en semanal, pero tal como está el mercado... HZNP
Ir a respuesta
28/09/15 16:22
Ha respondido al tema Farmas USA
Recompradas en 21,22 las vendidas el día 01/09 a 29,25. Espero no haberme precipitado HZNP
Ir a respuesta
25/09/15 15:31
Ha respondido al tema Farmas USA
Buenas noticias y reflejándose en la cotización. Horizon Pharma plc Receives Positive CHMP Opinion for RAVICTI(R) (Glycerol Phenylbutyrate) Oral Liquid for the Treatment of Urea Cycle Disorders in Patients Greater Than Two Months of Aje. HRZP http://ir.horizon-pharma.com/secfiling.cfm?filingid=1193125-15-327992&CIK=1492426
Ir a respuesta
24/09/15 17:07
Ha respondido al tema Farmas USA
Cruzó como un bólido la media de 50 sesiones en 23,88 y se va directa a tapar el gap en 22,65, si ahí no se para se encenderá la luz roja. HZNP
Ir a respuesta
22/09/15 19:01
Ha respondido al tema Farmas USA
No había leído tu post, pero creo que pensamos lo mismo. Y eso no es dar la brasa, es dar info y de la buena.
Ir a respuesta
22/09/15 18:57
Ha respondido al tema Farmas USA
Jeffrey Sherman vendió 7750 títulos, pero aún conserva 105000. Yo no creo que eso sea importante, se lo achaco a alguna necesidad de efectivo. Hablamos de una empresa con un 85% de institucionales, ese no puede ser el motivo. Pienso mas en una posible diluccion para hacer frente a la opa. Yo vendí el día 1/09 dos tercios de mi posición en 29,25 y ahora dudo entre vender el otro tercio o recomprar, pero le temo a los gaps que tiene por abajo. Creo que voy a esperar a ver como se mueve mañana.
Ir a respuesta
22/09/15 18:37
Ha respondido al tema Farmas USA
OK Framus, me he expresado mal, la noticia es de hoy, el precio objetivo es de julio 2015. Lo que quiero decir es que no encuentro nada que justifique esta bajada tan desproporcionada con relación a la media del mercado. HZNP
Ir a respuesta
22/09/15 18:14
Ha respondido al tema Farmas USA
A ver si alguno puede aclarar este entuerto: ¿Como es posible que hoy mismo 6 analistas pongan precio objetivo de 41,83 para HZNP y la acción esté ahora bajando más de un 13%? Zacks Short Term Rating on Horizon Pharma plc As many as 7 brokerage firms have rated Horizon Pharma plc (NASDAQ:HZNP) at 1.07. Research Analysts at Zacks have ranked the company at 3, suggesting the traders with a rating of hold for the short term. 1 analysts suggested buying the company. 6 analysts rated the company as a strong buy. Horizon Pharma plc (NASDAQ:HZNP): 6 analysts have set the short term price target of Horizon Pharma plc (NASDAQ:HZNP) at $41.83. The standard deviation of short term price target has been estimated at $5.27, implying that the actual price may fluctuate by this value. The higher and the lower price estimates are $ 51 and $37 respectively. Horizon Pharma plc (NASDAQ:HZNP) witnessed a decline in the market cap on Monday as its shares dropped 9.18% or 2.93 points. After the session commenced at $31.78, the stock reached the higher end at $32.34 while it hit a low of $28.73. With the volume soaring to 8,239,357 shares, the last trade was called at $28.99. The company has a 52-week high of $39.49. The company has a market cap of $4,615 million and there are 159,209,000 shares in outstanding. The 52-week low of the share price is $10.15. On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange, The Securities and Exchange Commission has divulged in a Form 4 filing that the director of Horizon Pharma Plc, Watkins Thomas had purchased shares worth of $313,200 in a transaction dated on August 19, 2015. A total of 10,000 shares were purchased at a price of $31.32 per share. The information is based on open market trades at the market prices.Option exercises are not covered. Currently the company Insiders own 0.2% of Horizon Pharma plc Company shares. In the past six months, there is a change of -5.04% in the total insider ownership. Institutional Investors own 87.5% of Company shares. During last 3 month period, 24.07% of total institutional ownership has changed in the company shares. Many analysts have commented on the company rating. Major Brokerage house, Piper Jaffray maintains its ratings on Horizon Pharma plc (NASDAQ:HZNP). In the latest research report, Piper Jaffray raises the target price from $38 per share to $48 per share on the shares. According to the information available, the shares are now rated Overweight by the analysts at the agency. The rating by the firm was issued on July 21, 2015. The company shares have rallied 167.56% in the past 52 Weeks. On July 20, 2015 The shares registered one year high of $39.49 and one year low was seen on October 15, 2014 at $10.15. The 50-day moving average is $30.87 and the 200 day moving average is recorded at $30.23. S&P 500 has rallied 1.82% during the last 52-weeks. Horizon Pharma Public Limited Company, (Horizon), formerly Horizon Pharma, Inc., is a biopharmaceutical company that develops and commercializes medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. On April 23, 2011, the United States Food and Drug Administration, approved DUEXIS (formerly HZT-501), a tablet formulation containing a fixed-dose combination of ibuprofen and famotidine in a single pill. The Companys other product, LODOTRA (NP-01), is a programmed release formulation of low-dose prednisone that is marketed in Europe by the Companys distribution partner, Mundipharma International Corporation Limited (Mundipharma). In September 2014, the Company acquired Vidara Therapeutics International plc. HZNP
Ir a respuesta
18/09/15 12:16
Ha respondido al tema Farmas USA
Abundante información comparativa sobre Horizon y Depomed, para la adquisición de esta última por parte de HZNP http://ir.horizon-pharma.com/secfiling.cfm?filingid=1193125-15-322452&CIK=1005201
Ir a respuesta
20/07/15 16:42
Ha respondido al tema Farmas USA
Vaya, parece que también voy a quedarme solo en EXEL. La tengo en mi cartera desde Mayo de 2012 a 4,42€; en diciembre de 2013 casi doblo, y desde ahí hasta el inframundo. Tengo fe en ella y me quedo a esperar su fase III. Se que nunca llegará a ser como Horizon, pero espero doblar antes de que termine 2016. Por cierto HORIZON cumpliendo plazos, 40€ antes de terminar 2015 y 50€ antes de 2017 EXEL
Ir a respuesta
29/05/15 17:03
Ha respondido al tema Farmas USA
Espero por tu bien que no hayas vendido ninguna. Tienes un gran precio de compra y me alegraría de no ser yo el único loco de este foro.
Ir a respuesta
Este sitio web usa cookies para analizar la navegación del usuario. Política de cookies.
Cerrar